Onco Wiki / drapeau rouge

Cancer endométrial 2L candidat avec une fonction adéquate de l'organe et com...

Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.

IDRF-ENDOMETRIAL-FIT-FOR-LENVATINIB-COMBO
TypeSignal d’alerte
Étatreviewed 2026-04-30 | pending_clinical_signoff
MaladiesDIS-ENDOMETRIAL
SourcesSRC-ESMO-ENDOMETRIAL-2022 SRC-NCCN-UTERINE-2025

Origine du drapeau rouge

DéfinitionEndometrial carcinoma 2L candidate with adequate organ function and controllable comorbidities to tolerate pembrolizumab + lenvatinib combination per KEYNOTE-775 (Makker NEJM 2022). Captures the prereq bundle: BP controllable on antihypertensives, no recent major surgery (<3 weeks), no active GI bleeding, no severe cardiac dysfunction (LVEF >=45%), and no uncontrolled proteinuria (UP/C <1.0 g/g) — these are the dose-modifying triggers for lenvatinib that, if uncontrolled at baseline, gate combination eligibility per FDA label.
Direction cliniqueintensifier
Catégorieaptitude physique
Algorithme de décalageALGO-ENDOMETRIAL-2L

Logique de déclenchement

{
  "all_of": [
    {
      "any_of": [
        {
          "finding": "uncontrolled_hypertension",
          "value": false
        },
        {
          "comparator": "<",
          "finding": "blood_pressure_systolic_mmhg",
          "threshold": 150
        }
      ]
    },
    {
      "any_of": [
        {
          "finding": "recent_surgery_within_3_weeks",
          "value": false
        },
        {
          "comparator": ">=",
          "finding": "weeks_since_last_surgery",
          "threshold": 3
        }
      ]
    },
    {
      "any_of": [
        {
          "finding": "active_gi_bleed",
          "value": false
        },
        {
          "finding": "gi_bleed_history_recent",
          "value": false
        }
      ]
    },
    {
      "any_of": [
        {
          "comparator": ">=",
          "finding": "lvef_percent",
          "threshold": 45
        },
        {
          "finding": "severe_cardiac_dysfunction",
          "value": false
        }
      ]
    },
    {
      "any_of": [
        {
          "finding": "proteinuria_uncontrolled",
          "value": false
        },
        {
          "comparator": "<",
          "finding": "up_c_ratio_g_per_g",
          "threshold": 1.0
        }
      ]
    }
  ],
  "type": "composite_score"
}

Notes

Aggregates the "Adequate organ function" + "lenvatinib toxicity tolerance required" gates from ALGO-ENDOMETRIAL-2L step 2. Each trigger axis defaults to "false" (i.e., NOT contraindicated) when finding absent — so patients without explicit contraindication documentation pass the gate. This is permissive-by-default which matches clinical practice (assume eligible unless documented ineligible). MDT brief should still surface lenvatinib-specific prerequisites for verbal confirmation. Patients flagged ineligible fall back to single-agent options (doxorubicin, paclitaxel re-challenge) outside current KB scope.

Utilisé par

Algorithmes